Tilomia 150 mg & 200 mg Capsules
PDF Leaflet Revision Date: 28 April 2021
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with Ph+ CML in chronic or accelerated phase.
Dosage (summary)
300 mg twice daily for newly diagnosed; 400 mg twice daily for resistant/intolerant patients.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; avoid breastfeeding during treatment.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- CYP3A4 inducers
Contraindications
- Hypersensitivity to nilotinib
Common side effects
- Rash
- Nausea
- Fatigue
- Headache
- Myelosuppression
Counselling Points
- Take on an empty stomach
- Monitor for signs of cardiac issues
- Report any severe side effects immediately
Serious warnings
- QT prolongation
- Myelosuppression
- Hepatitis B reactivation
Important Disclaimer
The Tilomia 150 mg & 200 mg Capsules professional information leaflet below is the property of Hetero Drugs South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
